A Study of Oral TP-3654 in Patients With Myelofibrosis


Study Number
622220
Phase
1
Purpose

This study is a Phase 1, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of TP-3654 in patients with intermediate-2 and high-risk primary or secondary MF.

Full Title

A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

ClinicalTrials.Gov ID
NCT04176198

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.